Dr Reddy’s Laboratories (DRL) has closed the acquisition of Habitrol brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health following issuance of the proposed consent order from the US Federal Trade Commission (FTC) recently.
The company had earlier entered into an asset purchase agreement with Novartis Consumer Health to acquire the title and rights of Habitrol brand and to market the product in the US market.
With this closure, the company has assumed responsibility for the product and will commence shipments of the product in the market shortly.
EP News Bureau – Mumbai